Sanofi Pasteur, a Sanofi Company
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sanofi Pasteur, a Sanofi Company sits in the top decile of US sponsors by registered trial count (#190 of 15,742 sponsors by registered trial count).
Sanofi Pasteur, a Sanofi Company: 153 sponsored US clinical trials, 3 recruiting.
Sanofi Pasteur, a Sanofi Company sponsors 153 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 132 completed. 71 of these trials are in Phase 3-4 (later-stage) and 67 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Influenza, with 16 trials.
Top-decile sponsor footprint
Sanofi Pasteur, a Sanofi Company ranks in the top decile of sponsors by registered trial count (#190 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
132 of 144 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
153 total, page 2 of 4
Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
NCT04460781
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
NCT03673462
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
NCT03617523
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
NCT03537508
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
NCT03308825
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
NCT03282240
Immunogenicity and Safety of a Purified Vero Rabies Vaccine
NCT03145766
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years
NCT03077438
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
NCT02915302
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
NCT02908269
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
NCT02842853
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
NCT02842866
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
NCT02752906
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier
NCT02633787
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
NCT02587520
Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry
NCT02554409
Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults
NCT02563093
A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older
NCT02553343
Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children
NCT02539108
Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults
NCT02258334
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
NCT02222870
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents
NCT02199691
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
NCT01943825
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
NCT01946425
Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults
NCT01946438
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
NCT01945424
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
NCT01887912
Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen
NCT01877395
Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use
NCT01784874
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
NCT01732627
Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
NCT01712984
Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.
NCT01691339
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
NCT01691326
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
NCT01659996
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
NCT01629589
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
NCT01488890
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose
NCT01439165
Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults
NCT01430819
Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine
NCT01442675
A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults
NCT01427309
Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children
NCT01689155
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
NCT01346293
Study of Quadrivalent Influenza Vaccine Among Children
NCT01240746
A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of Age
NCT01258595
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
NCT01230957
Study of Quadrivalent Influenza Vaccine Among Adults
NCT01218646
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
NCT01129362
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
NCT01049035
A Study of Influenza Virus Vaccines in Children and Adults
NCT00988143
Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM
NCT01011049
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 36 |
| Phase 3 | 33 |
| Phase 4 | 38 |
Therapeutic Areas
What is open in the Sanofi Pasteur, a Sanofi Company pipeline
3 recruiting of 153 indexed (2% open); 132 completed (86%).
Phase mix: 71 late (III/IV) vs 67 early (I/II) (balanced across stages).
Top condition: Influenza (16 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sanofi Pasteur, a Sanofi Company: open-pipeline peers nationwide
Peers matched on 153 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Sanofi Pasteur, a Sanofi Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 153 trials (± recruiting share)
- Gynecologic Oncology Group · 154 trials · 1% recruiting
- University of South Carolina · 157 trials · 19% recruiting
- Galderma R&D · 158 trials · 4% recruiting
- Pfizer's Upjohn has merged with Mylan to form Viatris · 158 trials · 0% recruiting
Sponsors near 2% open enrollment (± trial volume)
- PTC Therapeutics · 2% recruiting · 52 trials
- Spectrum Pharmaceuticals · 2% recruiting · 52 trials
- Carelon Research · 2% recruiting · 50 trials
- Société des Produits Nestlé (SPN) · 2% recruiting · 53 trials
Related
What to do with this Sanofi Pasteur, a Sanofi Company page
153 registered trials is a research-attention snapshot, not an endorsement of Sanofi Pasteur, a Sanofi Company or any single study.
- 3 of Sanofi Pasteur, a Sanofi Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Influenza is the condition Sanofi Pasteur, a Sanofi Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Influenza trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sanofi Pasteur, a Sanofi Company pipeline card: 153 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.